Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4 S Shibata, J Zhang, J Puthumana, KL Stone, RP Lifton Proceedings of the National Academy of Sciences 110 (19), 7838-7843, 2013 | 253 | 2013 |
Biomarkers of inflammation and repair in kidney disease progression J Puthumana, H Thiessen-Philbrook, L Xu, SG Coca, AX Garg, ... The Journal of clinical investigation 131 (3), 2021 | 121 | 2021 |
Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review SG Mansour, J Puthumana, SG Coca, M Gentry, CR Parikh BMC nephrology 18, 1-13, 2017 | 111 | 2017 |
Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation S Shibata, JP Arroyo, M Castañeda-Bueno, J Puthumana, J Zhang, ... Proceedings of the National Academy of Sciences 111 (43), 15556-15561, 2014 | 89 | 2014 |
Urine interleukin 18 and lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: a systematic review and meta-analysis J Puthumana, X Ariza, JM Belcher, I Graupera, P Ginès, CR Parikh Clinical Gastroenterology and Hepatology 15 (7), 1003-1013. e3, 2017 | 87 | 2017 |
Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017 AD Zhang, J Puthumana, NS Downing, ND Shah, HM Krumholz, JS Ross JAMA Network Open 3 (4), e203284-e203284, 2020 | 76 | 2020 |
Relationship of kidney injury biomarkers with long-term cardiovascular outcomes after cardiac surgery CR Parikh, J Puthumana, MG Shlipak, JL Koyner, H Thiessen-Philbrook, ... Journal of the American Society of Nephrology 28 (12), 3699-3707, 2017 | 69 | 2017 |
Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation J Puthumana, JD Wallach, JS Ross Jama 320 (3), 301-303, 2018 | 57 | 2018 |
YKL-40 associates with renal recovery in deceased donor kidney transplantation J Puthumana, IE Hall, PP Reese, B Schröppel, FL Weng, ... Journal of the American Society of Nephrology 28 (2), 661-670, 2017 | 54 | 2017 |
Phosphorylation by PKC and PKA regulate the kinase activity and downstream signaling of WNK4 M Castañeda-Bueno, JP Arroyo, J Zhang, J Puthumana, O Yarborough III, ... Proceedings of the National Academy of Sciences 114 (5), E879-E886, 2017 | 53 | 2017 |
Availability of investigational medicines through the US Food and Drug Administration’s expanded access and compassionate use programs J Puthumana, JE Miller, J Kim, JS Ross JAMA Network Open 1 (2), e180283-e180283, 2018 | 30 | 2018 |
Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration J Puthumana, AC Egilman, AD Zhang, JL Schwartz, JS Ross JAMA Internal Medicine 181 (4), 559-560, 2021 | 29 | 2021 |
Characteristics of clinical studies used for US Food and Drug Administration supplemental indication approvals of drugs and biologics, 2017 to 2019 M Dhodapkar, AD Zhang, J Puthumana, NS Downing, ND Shah, JS Ross JAMA Network Open 4 (6), e2113224-e2113224, 2021 | 23 | 2021 |
Associations between deceased-donor urine MCP-1 and kidney transplant outcomes SG Mansour, J Puthumana, PP Reese, IE Hall, MD Doshi, FL Weng, ... Kidney international reports 2 (4), 749-758, 2017 | 22 | 2017 |
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis AD Zhang, J Puthumana, NS Downing, ND Shah, H Krumholz, JS Ross medRxiv, 2019 | 7 | 2019 |
Characteristics of preapproval and postapproval studies of vaccines granted accelerated approval by the US Food and Drug Administration A Egilman, JD Wallach, J Puthumana, AD Zhang, JL Schwartz, JS Ross Journal of General Internal Medicine 36 (10), 3281-3284, 2021 | 2 | 2021 |
Demographic characteristics of participants in trials essential to US Food and Drug Administration vaccine approvals, 2010–2020 AD Zhang, J Puthumana, AC Egilman, JL Schwartz, JS Ross Journal of General Internal Medicine, 1-3, 2021 | 2 | 2021 |
Early experience with the FDA’s regulatory review of novel gene therapies J Puthumana, AC Egilman, R Ramachandran, N Naushad, N Shah, ... BMJ evidence-based medicine 27 (4), 195-198, 2022 | | 2022 |
CHARACTERIZING THE EVIDENCE SUPPORTING SUPPLEMENTAL INDICATION APPROVALS FOR DRUGS AND BIOLOGICS BY THE FDA, 2017 TO 2019 M Dhodapkar, AD Zhang, J Puthumana, NS Downing, ND Shah, JS Ross JOURNAL OF GENERAL INTERNAL MEDICINE 36 (SUPPL 1), S81-S82, 2021 | | 2021 |
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents over Three Decades, 1995-2017 A Zhang, J Puthumana, N Shah, J Ross 2019 Annual Research Meeting, 2019 | | 2019 |